Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiogenesis plays an important role in tumor growth and metastasis; therefore, inhibition of angiogenesis is a promising strategy for developing new anticancer drugs. Type 2 methionine aminopeptidase (MetAP2) protein is likely a molecular target of angiogenesis inhibitors. METHODS: Nitroxoline, an antibiotic used to treat urinary tract infections, was identified from a high-throughput screen of a library of 175,000 compounds for MetAP2 inhibitors and from a parallel screen using the Johns Hopkins Drug Library to identify currently used clinical drugs that can also inhibit human umbilical vein endothelial cells (HUVEC) proliferation. To investigate the mechanism of action of nitroxoline, inhibition of MetAP2 activity and induction of senescence were assessed in HUVEC. To test the antiangiogenic activity of nitroxoline, endothelial tube formation in Matrigel and microvessel formation in Matrigel plugs in vivo were assessed. Antitumor efficacy of nitroxoline was evaluated in mouse models of human breast cancer xenograft (n = 10) and bladder cancer orthotopic xenograft (n = 11). Furthermore, the mechanism of action of nitroxoline was investigated in vivo. RESULTS: Nitroxoline inhibited MetAP2 activity in vitro (half maximal inhibitory concentration [IC(50)] = 54.8 nM, 95% confidence interval [CI] = 22.6 to 132.8 nM) and HUVEC proliferation (IC(50) = 1.9 μM, 95% CI = 1.54 to 2.39 μM). Nitroxoline inhibited MetAP2 activity in HUVEC in a dose-dependent manner and induced premature senescence in a biphasic manner. Nitroxoline inhibited endothelial tube formation in Matrigel and reduced microvessel density in vivo. Mice (five per group) treated with nitroxoline showed a 60% reduction in tumor volume in breast cancer xenografts (tumor volume on day 30, vehicle vs nitroxoline, mean = 215.4 vs 86.5 mm(3), difference = 128.9 mm(3), 95% CI = 32.9 to 225.0 mm(3), P = .012) and statistically significantly inhibited growth of bladder cancer in an orthotopic mouse model (tumor bioluminescence intensities of vehicle [n = 5] vs nitroxoline [n = 6], P = .045). CONCLUSION: Nitroxoline shows promise as a potential therapeutic antiangiogenic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“The synergistic activity between two drugs in inhibiting HUVEC proliferation was calculated mathematically based on ChouTalalay combination index equation (41).”
MethodStress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 1×
“Greenberg and was obtained through Addgene (Cambridge, MA) (36).”
MethodDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Sherr, C. J., & DePinho, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00046-5 · Cited by 745
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Self-citationSIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth
Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Mione, M., Dejana, E., Alt, F. W., et al. (2007) · Genes & Development · doi:10.1101/gad.435107 · Cited by 608 · cited 1×
“Previously, it has been shown that SIRT1 inhibition was sufficient to inhibit angiogenesis both in vitro and in vivo (52).”
Background
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382
Self-citationCancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 340
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
8-Hydroxyquinolines in medicinal chemistry: A structural perspective
Oliveri, V., & Vecchio, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.007 · Cited by 281
Metadata
- Authors
- Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H.-E. C., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., So, A., & Liu, J. O.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-18
- Volume
- 102
- Issue
- 24
- Pages
- 1855-1873
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2167872699
- Cited by
- 112
- References
- 6
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer. https://app.cochat.ai/papers/10.1093/jnci/djq457
- The paper
- Shim, J. S., Matsui, Y., Bhat, S., Nacev, B. A., Xu, J., Bhang, H.-E. C., Dhara, S., Han, K. C., Chong, C. R., Pomper, M. G., So, A., & Liu, J. O. (2010). Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djq457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.